Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA

References

• Auwärter V, Dresen S, Weinmann W, et al. “Spice” and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44:832–837.
   PubMed Web of Science ®Google Scholar
• Castellanos D. Synthetic cannabinoids 2015: an update for pediatricians in clinical practice. World J Clin Pediatr. 2016;5:16.
   PubMedGoogle Scholar
• Wiley JL, Marusich JA, Thomas BF. Combination chemistry: structure-activity relationships of novel psychoactive cannabinoids. Curr Top Behav Neurosci. 2017;32:231–248.
   PubMedGoogle Scholar
• Laprairie RB, Bagher AM, Denovan-Wright EM. Cannabinoid receptor ligand bias: implications in the central nervous system. Curr Opin Pharmacol. 2016;32:32–43.
   PubMed Web of Science ®Google Scholar
• EMCDDA | European Drug Report 2014 — full package and event information [Internet]; [cited 2014 Oct 22]. Available from: http://www.emcdda.europa.eu/edr2014
   Google Scholar
• ACMD Advisory Council on the Misuse of Drugs. Third generation’ synthetic cannabinoids [Internet]; [cited 2017 Mar 9]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/380161/CannabinoidsReport.pdf
   Google Scholar
• Buchler IP, Hayes MJ, Hedge SG, et al. “Indazol Derivatives”, United States Patent WO 2009/106980 A2 [Internet]; 2009. Available from: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009106980&recNum =149&docAn=IB2009000409&queryString=%28PA/Pfizer%29%2520&maxRec =2414
   Google Scholar
• Franz F, Angerer V, Moosmann B, et al. Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples: detection of MDMB-CHMICA consumption in human urine. Drug Test Anal. [Internet]; 2016 [cited 2016 Aug 17]. Available from: http://doi.wiley.com/10.1002/dta.2049
   Google Scholar
• Brents LK, Reichard EE, Zimmerman SM, et al. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011;6:e21917.
   Google Scholar
• Tyndall JA, Gerona R, De Portu G, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol. 2015;53:950–956.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Kneisel S, Szabo B, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings: acute intoxications by synthetic cannabinoids. Addiction. 2013;108:534–544.
   PubMed Web of Science ®Google Scholar
• Angerer V, Süszenbach F, Hirschinger N, et al. Validated LC–MS/MS method for qualitative and quantitative analysis of 75 synthetic cannabinoids in serum. 53rd Annual Meeting of Internationa Association of Forensic Toxicology, TIAFT; 2015. p. 126.
   Google Scholar
• Franz F, Angerer V, Jechle H, et al. Immunoassay screening in urine for synthetic cannabinoids – an evaluation of the diagnostic efficiency. Clin Chem Lab Med. 2017;55:1375–1384.
   PubMed Web of Science ®Google Scholar
• Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol. 2016;54:1–13.
   PubMed Web of Science ®Google Scholar
• Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int. 2016;261:e5–e10.
   PubMed Web of Science ®Google Scholar
• Westin AA, Frost J, Brede WR, et al. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol. 2016;40:86–87.
   PubMed Web of Science ®Google Scholar
• Hill SL, Najafi J, Dunn M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol. 2016;54:638–643.
   PubMed Web of Science ®Google Scholar
• Seywright A, Torrance HJ, Wylie FM, et al. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. Clin Toxicol. 2016;54:632–637.
   PubMed Web of Science ®Google Scholar
• Meyyappan C, Ford L, Vale A. Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist. Clin Toxicol. 2017;55:151–152.
   PubMed Web of Science ®Google Scholar
• Bäckberg M, Tworek L, Beck O, et al. Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA project. J Med Toxicol. 2017;13:52–60.
   PubMed Web of Science ®Google Scholar
• Abouchedid R, Hudson S, Thurtle N, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Clin Toxicol. 2017;55:338–345.
   PubMed Web of Science ®Google Scholar
• Thundiyil JG, Rowley F, Papa L, et al. Risk factors for complications of drug-induced seizures. J Med Toxicol. 2011;7:16–23.
   PubMedGoogle Scholar
• Maas M, Naidech A. Critical care neurology perspective on delirium. Semin Neurol. 2016;36:601–606.
   PubMed Web of Science ®Google Scholar
• Lam RPK, Yip WL, Wan CK, et al. Dexmedetomidine use in the emergency department for control of methamphetamine-induced agitation. A report of two cases. Am J Emerg Med. 2017;35:665.e1–665.e4.
   Web of Science ®Google Scholar
• Colizzi M, McGuire P, Pertwee RG, et al. Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci Biobehav Rev. 2016;64:359–381.
   PubMed Web of Science ®Google Scholar
• Le Boisselier R, Alexandre J, Lelong-Boulouard V, et al. Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther. 2017;101:220–229.
   PubMed Web of Science ®Google Scholar
• Broyd SJ, van Hell HH, Beale C, et al. Acute and chronic effects of cannabinoids on human cognition—a systematic review. Biol Psychiatry. 2016;79:557–567.
   PubMed Web of Science ®Google Scholar
• Takematsu M, Hoffman RS, Nelson LS, et al. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol. 2014;52:973–975.
   Web of Science ®Google Scholar
• Hermanns-Clausen M, Kithinji J, Spehl M, et al. Adverse effects after the use of JWH-210 – a case series from the EU Spice II plus project: case series of JWH-210 intoxications. Drug Test Anal. 2016;8:1030–1038.
   PubMed Web of Science ®Google Scholar
• Wiley JL, Marusich JA, Huffman JW. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 2014;97:55–63.
   PubMed Web of Science ®Google Scholar
• Wiley JL, Marusich JA, Lefever TW, et al. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology. 2013;75:145–154.
   PubMed Web of Science ®Google Scholar
• Banister SD, Longworth M, Kevin R, et al. Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci. 2016;7:1241–1254.
   PubMed Web of Science ®Google Scholar
• Gudsoorkar VS, Perez JA. A new differential diagnosis: synthetic cannabinoids-associated acute renal failure. Methodist DeBakey Cardiovasc J. 2015;11:189–191.
   PubMedGoogle Scholar
• Kamel M, Thajudeen B. A case of acute kidney injury and calcium oxalate deposition associated with synthetic cannabinoids. Saudi J Kidney Dis Transplant. 2015;26:802.
   PubMed Web of Science ®Google Scholar
• Angerer V, Franz F, Schwarze B, et al. Reply to “Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA”. J Anal Toxicol. 2016;40:240–242.
   PubMed Web of Science ®Google Scholar